AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma.
AI discovered a drug against a previously untargetable protein, suppressing pancreatic tumors and extending survival in early models.
AI-driven computational modeling identifies GIPCi, a selective small-molecule inhibitor of the GIPC1 PDZ domain (previously considered 'undruggable'); HDX-MS confirms direct binding; GIPCi alone or with gemcitabine significantly suppresses PDAC tumor growth and improves survival in patient-derived organoid and xenograft models. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- experimental (AI-assisted drug discovery + in vitro + in vivo validation)
- Category
- precision_oncology
- Maturity
- Exploratory
- Journal
- Cell Rep
Why it surfaced
Addresses a key unmet need (PDAC, <13% 5-yr survival); demonstrates AI-driven drug discovery unlocking a previously undruggable target; Cell Reports publication with multi-model validation including patient-derived organoids; directly relevant to the precision oncology AI-drug discovery pipeline.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.